医学
髓系白血病
白血病
CD135型
造血干细胞移植
慢性淋巴细胞白血病
人口
疾病
肿瘤科
免疫学
酪氨酸激酶
移植
嵌合抗原受体
疾病负担
入射(几何)
内科学
靶向治疗
慢性白血病
急性白血病
髓样
造血
流行病学
造血干细胞
急性淋巴细胞白血病
重症监护医学
干细胞
儿科
作者
Hu Lijuan,Xia Yi,Huang Xiaojun
标识
DOI:10.21147/j.issn.1000-9604.2025.06.03
摘要
This comprehensive review integrates population-based registries, hospital databases and Global Burden of Disease data to describe the evolving leukemia burden in China from 2000 to 2022. The overall incidence has stabilized nationally, but the absolute number of cases continues to increase as the population ages. A bimodal age pattern persists, with acute leukemias clustering in young children and older adults, while chronic forms predominate in mid-to-late life, and males are consistently more affected by all subtypes. Rapid expansion of haploidentical hematopoietic stem cell transplantation has resulted in marked survival gains for both acute myeloid leukemia and acute lymphoblastic leukemia, and its seamless integration with molecularly targeted agents, venetoclax-based regimens and chimeric antigen receptor T-cell therapy has transformed acute leukemias into potentially curable diseases for an expanding proportion of patients. In parallel, universal access to tyrosine kinase inhibitors and standardized molecular monitoring have turned chronic myeloid leukemia into a manageable chronic condition, and survival of patients with chronic lymphocytic leukemia is improving as novel Bruton's tyrosine kinase and BCL-2 inhibitors diffuse into clinical practice. Tobacco, obesity, benzene and radon remain the principal modifiable drivers of leukemogenesis. Strengthening data completeness, widening equitable access to precision therapies and controlling these environmental risks are essential to sustaining the observed continuous improvement in leukemia patient survival and ensuring that ever more Chinese patients achieve a cure or durable disease control in the decades ahead.
科研通智能强力驱动
Strongly Powered by AbleSci AI